Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 960539-70-2
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the use of daprodustat during breastfeeding. Because of relatively high protein binding, the amount in milk is likely to be low. The manufacturer recommends that breastfeeding be discontinued during daprodustat therapy and for one week after the final dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Daprodustat
CAS Registry Number
960539-70-2
Drug Class
Breast Feeding
Lactation
Milk, Human
Enzyme Inhibitors
Prolyl-Hydroxylase Inhibitors
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- Review Repotrectinib.[Drugs and Lactation Database (...]Review Repotrectinib.. Drugs and Lactation Database (LactMed®). 2006
- Discovery and Preclinical Characterization of GSK1278863 (Daprodustat), a Small Molecule Hypoxia Inducible Factor-Prolyl Hydroxylase Inhibitor for Anemia.[J Pharmacol Exp Ther. 2017]Discovery and Preclinical Characterization of GSK1278863 (Daprodustat), a Small Molecule Hypoxia Inducible Factor-Prolyl Hydroxylase Inhibitor for Anemia.Ariazi JL, Duffy KJ, Adams DF, Fitch DM, Luo L, Pappalardi M, Biju M, DiFilippo EH, Shaw T, Wiggall K, et al. J Pharmacol Exp Ther. 2017 Dec; 363(3):336-347. Epub 2017 Sep 19.
- Review Dabrafenib.[Drugs and Lactation Database (...]Review Dabrafenib.. Drugs and Lactation Database (LactMed®). 2006
- Review Lapatinib.[Drugs and Lactation Database (...]Review Lapatinib.. Drugs and Lactation Database (LactMed®). 2006
- Review Belantamab Mafodotin.[Drugs and Lactation Database (...]Review Belantamab Mafodotin.. Drugs and Lactation Database (LactMed®). 2006
- Daprodustat - Drugs and Lactation Database (LactMed®)Daprodustat - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...